Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension in Noncirrhotic Patients with Portal Cavernoma

Table 1

Patient characteristics, previous history of splenectomy, imaging studies, and laboratory results.

Patient number/age (y)/sex	Underlying prothrombotic disorders	Imaging studies	TBIL; (μmol/L)	ALT; (U/L)	AST; (U/L)	ALP; (U/L)	WBC; (109/L)	Platelet; (109/L)	Splenectomy
1/35/F	N/A	Total occluded MPV and SMV	10.2	12	15	79	4.94	122	Yes
2/24/M	N/A	Partial occluded MPV	9.4	23	50	73	2.76	45	Yes
3/39/M	N/A	Total occluded MPV and SV and partial occluded SMV	11.3	11	25	75	9.77	6	No
4/19/M	Antithrombin III deficiency, thrombocytosis	Total occluded MPV	15.3	57	86	59	1.83	472	Yes
5/25/F	Protein C deficiency, antithrombin III deficiency	Total occluded MPV and partial occluded SMV and SV	36.4	37	32	166	4.37	25	No
6/26/M	N/A	Partial occluded MPV	10.4	17	25	112	2.51	71	Yes
7/25/F	Thrombocytosis	Total occluded MPV	6.4	29	33	70	2.63	653	Yes
8/40/M	Antithrombin III deficiency	Partial occluded MPV	7.7	19	26	96	4.17	216	No
9/21/F	No	Total occluded MPV and SMV	15.6	29	19	101	14.26	185	Yes
10/19/M	Antithrombin III deficiency	Total occluded MPV and partial occluded SMV	19.6	16	33	68	3.41	51	No
11/34/M	Protein C deficiency	Total occluded MPV, partial occluded SMV and SV	13.8	13	26	72	2.42	52	No
12/45/M	No	Total occluded MPV and SMV	19	13	21	145	2.15	277	Yes
13/31/M	Thrombocytosis	Total occluded MPV and SMV	10.8	15	23	67	1.27	517	Yes
14/29/M	FVL mutation, protein C deficiency	Total occluded MPV and partial occluded SMV	6	26	24	63	3.54	189	Yes
15/24/M	Protein S deficiency	Partial occluded MPV	8.1	10	16	38	7.68	92	No

TBIL: total bilirubin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, WBC: white blood cell, MPV: main portal vein, SMV: superior mesenteric vein, SV: splenic vein, and FVL mutation: Factor V Leiden mutation.